Matthew Vincent Dolan, EVP Strategy and Corporate Development at DEXCOM INC (DXCM), sold 3,980 shares at $137.81 ($548K) on 2024-04-15, disclosed to the SEC on 2024-04-16.
Scheduled sale ($548k) by EVP Strategy and Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $137.81 | 1,990 | $274K | 50.0% |
| 2 | $137.81 | 1,990 | $274K | 50.0% |
| Total | $137.81 avg | 3,980 | $548K | 100% |
| Filing → |
| DXCM | SELL | 2024-03-19 | $1.1M | — | Filing → |
| DXCM | SELL | 2024-03-14 | $1.8M | — | Filing → |
| DXCM | SELL | 2023-09-01 | $6K | — | Filing → |